Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Clearmind Medicine is evaluating its lead candidate, CMND-100 (MEAI), for potential FDA Breakthrough Therapy Designation based on positive results from a clinical trial for Alcohol Use Disorder. The company's treatment is a non-hallucinogenic, second-generation neuroplastogen-derived therapeutic.
Clearmind Medicine Inc. is evaluating its lead candidate, CMND-100 (MEAI), for potential FDA Breakthrough Therapy Designation. The decision is based on positive results from an ongoing FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder. The FDA's Breakthrough Therapy Designation is granted to drugs that treat serious or life-threatening conditions with substantial improvement over existing therapies. Alcohol Use Disorder is a life-threatening condition with a significant unmet medical need. Clearmind Medicine remains committed to science-driven development and looks forward to continued engagement with the FDA. The company has not submitted a request for Breakthrough Therapy Designation for MEAI as of the date of the announcement.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.